Richter may postpone guidance pending Esmya review
Hungarian drugmaker Gedeon Richter may hold off on guidance when it publishes fourth-quarter earnings in February if uncertainty continues surrounding Esmya, its drug for the treatment of uterine cysts, CEO Gábor Orbán told news wire Reuters late Friday.
Orbán told Reuters that if current levels of uncertainty around Esmya persist, Richter may not issue its earnings guidance on February 8, when it is scheduled to publish Q4 earnings, Hungarian news agency MTI reported today.
Richter confirmed early in December that the European Medicines Agency (EMA) had started a review of Esmya after reports of serious liver damage in four patients treated with the drug.
Richterʼs communications director Zsuzsa Beke said at the time that available clinical data showed no link between Esmya and liver damage in the patients, adding that the cause may have been the use of other drugs at the same time or viral infections.
The EMA is expected to deliver a ruling on the drug in the first half of 2018, Orbán told Reuters. Richter earlier projected that sales of Esmya would reach EUR 85 million in 2017, MTI noted.
Esmya was approved by European Commission officials for long-term management of uterine fibroids in May 2015.
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.